Hamburg on how COVID-19 collaboration models could propel drug development for public health priorities: a BioCentury audio interview

The extraordinary collaboration and commitment on the part of biopharma companies and governments that COVID-19 has inspired should serve as models for addressing unmet medical needs after the crisis has passed, Margaret Hamburg, who served as FDA Commissioner in 2009-15, told BioCentury.

“We've seen the ecosystem of medical product development behaving very differently in the context of COVID, and I think there are important lessons to be learned and applied going forward,” said Hamburg in a BioCentury Back to School audio interview. The conversation was one of a series of BioCentury’s Back to School 2020 audio interviews with industry leaders (see Cover Story: “The Imperative of COVID-19”). ...